Increased Percentage of HLA-DR T Cells in Untreated Juvenile Dermatomyositis

Overview

Journal Clin Immunol Commun

Specialty Allergy & Immunology

Date 2024 Jul 4

PMID 38962376

Authors

Amer Khojah

Madeline Schutt

Gabrielle Morgan

Ameera Bukhari

Nicolas Bensen

Aaruni Khanolkar

Lauren M Pachman

Affiliations

Soon will be listed here.

Abstract

This study investigates HLA-DR expression on activated T cells and serum neopterin levels in Juvenile Dermatomyositis (JDM) children pre- and post-treatment. Sixty-nine JDM children (less than 18 years) were included. Elevated HLA-DR+ cells (>7 %) were observed in 19 % of untreated cases. Post-treatment, mean HLA-DR+ cells decreased from 5.1 to 2.9 ( < 0.001), and serum neopterin levels declined from 19.3 to 9.1 nmol/L ( < 0.0001). A positive correlation between serum neopterin and HLA-DR T cell percentage was observed ( = 0.39, = 0.01). Intravenous steroid treatment exhibited a 47.4 % improvement in HLA-DR+ cells and a 50.5 % reduction in serum neopterin levels, in contrast to 14.8 % and 34.1 % in the oral steroid group. In conclusion, treatment, particularly with IV steroids, significantly improved HLA-DR+ cells percentage and neopterin levels. A correlation between HLA-DR+ cells percentage and serum neopterin was noted in untreated JDM patients.

Citing Articles

Dyslipidemia in Juvenile Dermatomyositis.

Khojah A, Morgan G, Kadakia A, Klein-Gitelman M, Pachman L Sci Rep. 2024; 14(1):26528.

PMID: 39489760 PMC: 11532421. DOI: 10.1038/s41598-024-77985-4.

Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness.

Khojah A, Pachman L, Bukhari A, Trinh C, Morgan G, Pandey S Int J Mol Sci. 2024; 25(13.

PMID: 39000234 PMC: 11241205. DOI: 10.3390/ijms25137126.

References

Khojah A, Morgan G, Klein-Gitelman M, Pachman L . Juvenile dermatomyositis: association between nail fold capillary end row loop- area under the curve- and disease damage indicators. Pediatr Rheumatol Online J. 2023; 21(1):137. PMC: 10641947. DOI: 10.1186/s12969-023-00919-3. View

Raziuddin S, Nur M, Al-Wabel A . Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Scand J Immunol. 1990; 31(2):139-45. DOI: 10.1111/j.1365-3083.1990.tb02753.x. View

Ma X, Gao H, Zhang Q, Yang M, Bi Z, Ji S . Endoplasmic Reticulum Stress Is Involved in Muscular Pathogenesis in Idiopathic Inflammatory Myopathies. Front Cell Dev Biol. 2022; 10:791986. PMC: 8882762. DOI: 10.3389/fcell.2022.791986. View

Khojah A, Liu V, Morgan G, Shore R, Pachman L . Changes in total body fat and body mass index among children with juvenile dermatomyositis treated with high-dose glucocorticoids. Pediatr Rheumatol Online J. 2021; 19(1):118. PMC: 8353815. DOI: 10.1186/s12969-021-00622-1. View

Pachman L, Nolan B, DeRanieri D, Khojah A . Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy. Curr Treatm Opt Rheumatol. 2021; 7(1):39-62. PMC: 8336914. DOI: 10.1007/s40674-020-00168-5. View

Papadopoulou C, Chew C, Wilkinson M, McCann L, Wedderburn L . Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023; 19(6):343-362. PMC: 10184643. DOI: 10.1038/s41584-023-00967-9. View

Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F . HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A. 2007; 104(16):6776-81. PMC: 1851664. DOI: 10.1073/pnas.0611244104. View

Lopez De Padilla C, Vallejo A, McNallan K, Vehe R, Smith S, Dietz A . Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007; 56(5):1658-68. DOI: 10.1002/art.22558. View

Costin C, Khojah A, Ochfeld E, Morgan G, Subramanian S, Klein-Gitelman M . B Cell Lymphocytosis in Juvenile Dermatomyositis. Diagnostics (Basel). 2023; 13(16). PMC: 10453137. DOI: 10.3390/diagnostics13162626. View

10.

Rouster-Stevens K, Gursahaney A, Ngai K, Daru J, Pachman L . Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008; 59(2):222-6. PMC: 2852143. DOI: 10.1002/art.23341. View

11.

Duvvuri B, Pachman L, Morgan G, Khojah A, Klein-Gitelman M, Curran M . Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. Arthritis Rheumatol. 2019; 72(2):348-358. DOI: 10.1002/art.41078. View

12.

Gibbs E, Khojah A, Morgan G, Ehwerhemuepha L, Pachman L . The von Willebrand Factor Antigen Reflects the Juvenile Dermatomyositis Disease Activity Score. Biomedicines. 2023; 11(2. PMC: 9953073. DOI: 10.3390/biomedicines11020552. View

13.

Pachman L, Morgan G, Klein-Gitelman M, Ahsan N, Khojah A . Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of disease activity. Pediatr Rheumatol Online J. 2023; 21(1):118. PMC: 10571265. DOI: 10.1186/s12969-023-00903-x. View

14.

Kim H, Gunter-Rahman F, McGrath J, Lee E, de Jesus A, Targoff I . Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther. 2020; 22(1):69. PMC: 7137415. DOI: 10.1186/s13075-020-02160-9. View

15.

Klein-Gitelman M, Waters T, Pachman L . The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res. 2003; 13(6):360-8. DOI: 10.1002/1529-0131(200012)13:6<360::aid-art5>3.0.co;2-q. View

16.

Pachman L, Khojah A . Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. J Pediatr. 2018; 195:16-27. PMC: 5881602. DOI: 10.1016/j.jpeds.2017.12.053. View

17.

Bukhari A, Khojah A, Marin W, Khramtsov A, Khramtsova G, Costin C . Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study. Int J Mol Sci. 2023; 24(13). PMC: 10341737. DOI: 10.3390/ijms241310553. View

18.

Costin C, Morgan G, Khojah A, Klein-Gitelman M, Pachman L . Lower NK cell numbers in children with untreated juvenile dermatomyositis during the COVID-19 pandemic. Clin Immunol Commun. 2023; 3:42-45. PMC: 9938532. DOI: 10.1016/j.clicom.2023.02.007. View

19.

Bode R, Klein-Gitelman M, Miller M, Lechman T, Pachman L . Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003; 49(1):7-15. DOI: 10.1002/art.10924. View

20.

Khojah A, Liu V, Savani S, Morgan G, Shore R, Bellm J . Association of p155/140 Autoantibody With Loss of Nailfold Capillaries but not Generalized Lipodystrophy: A Study of Ninety-Six Children With Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2020; 74(7):1065-1069. DOI: 10.1002/acr.24535. View